Is colchicine prophylaxis required with start-low go-slow allopurinol dose escalation in gout? A non-inferiority randomised double-blind placebo-controlled trial
© Author(s) (or their employer(s)) 2023. No commercial re-use. See rights and permissions. Published by BMJ..
OBJECTIVES: To determine whether placebo is non-inferior to low-dose colchicine for reducing gout flares during the first 6 months of allopurinol using the 'start-low go-slow' dose approach.
METHODS: A 12-month double-blind, placebo-controlled non-inferiority trial was undertaken. Adults with at least one gout flare in the preceding 6 months, fulfilling the American College of Rheumatology (ACR) recommendations for starting urate-lowering therapy and serum urate ≥0.36 mmol/L were recruited. Participants were randomised 1:1 to colchicine 0.5 mg daily or placebo for the first 6 months. All participants commenced allopurinol, increasing monthly to achieve target urate <0.36 mmol/L. The primary efficacy outcome was the mean number of gout flares/month between 0 and 6 months, with a prespecified non-inferiority margin of 0.12 gout flares/month. The primary safety outcome was adverse events over the first 6 months.
RESULTS: Two hundred participants were randomised. The mean (95% CI) number of gout flares/month between baseline and month 6 was 0.61 (0.47 to 0.74) in the placebo group compared with 0.35 (0.22 to 0.49) in the colchicine group, mean difference 0.25 (0.07 to 0.44), non-inferiority p=0.92. There was no difference in the mean number of gout flares/month between randomised groups over the 12-month period (p=0.68). There were 11 serious adverse events in 7 participants receiving colchicine and 3 in 2 receiving placebo.
CONCLUSIONS: Placebo is not non-inferior to colchicine in prevention of gout flares in the first 6 months of starting allopurinol using the 'start-low go-slow' strategy. After stopping colchicine, gout flares rise with no difference in the mean number of gout flares/month between groups over a 12-month period.
TRIAL REGISTRATION NUMBER: ACTRN 12618001179224.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2023 |
---|---|
Erschienen: |
2023 |
Enthalten in: |
Zur Gesamtaufnahme - volume:82 |
---|---|
Enthalten in: |
Annals of the rheumatic diseases - 82(2023), 12 vom: 29. Dez., Seite 1626-1634 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Stamp, Lisa [VerfasserIn] |
---|
Links: |
---|
Themen: |
268B43MJ25 |
---|
Anmerkungen: |
Date Completed 13.11.2023 Date Revised 22.11.2023 published: Print-Electronic ANZCTR: ACTRN12618001179224 Citation Status MEDLINE |
---|
doi: |
10.1136/ard-2023-224731 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM361504810 |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | NLM361504810 | ||
003 | DE-627 | ||
005 | 20231226085258.0 | ||
007 | cr uuu---uuuuu | ||
008 | 231226s2023 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1136/ard-2023-224731 |2 doi | |
028 | 5 | 2 | |a pubmed24n1204.xml |
035 | |a (DE-627)NLM361504810 | ||
035 | |a (NLM)37652661 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Stamp, Lisa |e verfasserin |4 aut | |
245 | 1 | 0 | |a Is colchicine prophylaxis required with start-low go-slow allopurinol dose escalation in gout? A non-inferiority randomised double-blind placebo-controlled trial |
264 | 1 | |c 2023 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Completed 13.11.2023 | ||
500 | |a Date Revised 22.11.2023 | ||
500 | |a published: Print-Electronic | ||
500 | |a ANZCTR: ACTRN12618001179224 | ||
500 | |a Citation Status MEDLINE | ||
520 | |a © Author(s) (or their employer(s)) 2023. No commercial re-use. See rights and permissions. Published by BMJ. | ||
520 | |a OBJECTIVES: To determine whether placebo is non-inferior to low-dose colchicine for reducing gout flares during the first 6 months of allopurinol using the 'start-low go-slow' dose approach | ||
520 | |a METHODS: A 12-month double-blind, placebo-controlled non-inferiority trial was undertaken. Adults with at least one gout flare in the preceding 6 months, fulfilling the American College of Rheumatology (ACR) recommendations for starting urate-lowering therapy and serum urate ≥0.36 mmol/L were recruited. Participants were randomised 1:1 to colchicine 0.5 mg daily or placebo for the first 6 months. All participants commenced allopurinol, increasing monthly to achieve target urate <0.36 mmol/L. The primary efficacy outcome was the mean number of gout flares/month between 0 and 6 months, with a prespecified non-inferiority margin of 0.12 gout flares/month. The primary safety outcome was adverse events over the first 6 months | ||
520 | |a RESULTS: Two hundred participants were randomised. The mean (95% CI) number of gout flares/month between baseline and month 6 was 0.61 (0.47 to 0.74) in the placebo group compared with 0.35 (0.22 to 0.49) in the colchicine group, mean difference 0.25 (0.07 to 0.44), non-inferiority p=0.92. There was no difference in the mean number of gout flares/month between randomised groups over the 12-month period (p=0.68). There were 11 serious adverse events in 7 participants receiving colchicine and 3 in 2 receiving placebo | ||
520 | |a CONCLUSIONS: Placebo is not non-inferior to colchicine in prevention of gout flares in the first 6 months of starting allopurinol using the 'start-low go-slow' strategy. After stopping colchicine, gout flares rise with no difference in the mean number of gout flares/month between groups over a 12-month period | ||
520 | |a TRIAL REGISTRATION NUMBER: ACTRN 12618001179224 | ||
650 | 4 | |a Randomized Controlled Trial | |
650 | 4 | |a Journal Article | |
650 | 4 | |a Research Support, Non-U.S. Gov't | |
650 | 4 | |a Crystal arthropathies | |
650 | 4 | |a Gout | |
650 | 4 | |a Therapeutics | |
650 | 7 | |a Allopurinol |2 NLM | |
650 | 7 | |a 63CZ7GJN5I |2 NLM | |
650 | 7 | |a Colchicine |2 NLM | |
650 | 7 | |a SML2Y3J35T |2 NLM | |
650 | 7 | |a Gout Suppressants |2 NLM | |
650 | 7 | |a Uric Acid |2 NLM | |
650 | 7 | |a 268B43MJ25 |2 NLM | |
700 | 1 | |a Horne, Anne |e verfasserin |4 aut | |
700 | 1 | |a Mihov, Borislav |e verfasserin |4 aut | |
700 | 1 | |a Drake, Jill |e verfasserin |4 aut | |
700 | 1 | |a Haslett, Janine |e verfasserin |4 aut | |
700 | 1 | |a Chapman, Peter T |e verfasserin |4 aut | |
700 | 1 | |a Frampton, Christopher |e verfasserin |4 aut | |
700 | 1 | |a Dalbeth, Nicola |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Annals of the rheumatic diseases |d 1939 |g 82(2023), 12 vom: 29. Dez., Seite 1626-1634 |w (DE-627)NLM000174114 |x 1468-2060 |7 nnns |
773 | 1 | 8 | |g volume:82 |g year:2023 |g number:12 |g day:29 |g month:12 |g pages:1626-1634 |
856 | 4 | 0 | |u http://dx.doi.org/10.1136/ard-2023-224731 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 82 |j 2023 |e 12 |b 29 |c 12 |h 1626-1634 |